PL1968612T3 - Proleki dinukleotydowe - Google Patents

Proleki dinukleotydowe

Info

Publication number
PL1968612T3
PL1968612T3 PL06848625.7T PL06848625T PL1968612T3 PL 1968612 T3 PL1968612 T3 PL 1968612T3 PL 06848625 T PL06848625 T PL 06848625T PL 1968612 T3 PL1968612 T3 PL 1968612T3
Authority
PL
Poland
Prior art keywords
dinucleotide
prodrugs
dinucleotide prodrugs
Prior art date
Application number
PL06848625.7T
Other languages
English (en)
Inventor
Radhakrishnan P. Iyer
Seetharamaiyer Padmanabhan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1968612T3 publication Critical patent/PL1968612T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL06848625.7T 2005-12-13 2006-12-13 Proleki dinukleotydowe PL1968612T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
PL1968612T3 true PL1968612T3 (pl) 2016-11-30

Family

ID=38194676

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16158945T PL3090748T3 (pl) 2005-12-13 2006-12-13 Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe
PL06848625.7T PL1968612T3 (pl) 2005-12-13 2006-12-13 Proleki dinukleotydowe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16158945T PL3090748T3 (pl) 2005-12-13 2006-12-13 Kompozycje zawierające proleki nukleotydowe i oligonukleotydowe

Country Status (17)

Country Link
US (6) US8076303B2 (pl)
EP (3) EP1968612B1 (pl)
JP (1) JP5044854B2 (pl)
KR (2) KR101123534B1 (pl)
CN (2) CN102796155B (pl)
CY (2) CY1117576T1 (pl)
DK (2) DK3090748T3 (pl)
ES (2) ES2729657T3 (pl)
HR (1) HRP20160531T1 (pl)
HU (2) HUE029190T2 (pl)
IN (1) IN2015DN01786A (pl)
LT (1) LT3090748T (pl)
PL (2) PL3090748T3 (pl)
PT (1) PT3090748T (pl)
RS (1) RS54867B1 (pl)
SI (2) SI1968612T1 (pl)
WO (1) WO2007070598A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292973T1 (de) * 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN102123716B (zh) 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法
WO2010039543A2 (en) * 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
CA2747999A1 (en) * 2008-12-23 2010-07-01 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
KR101885383B1 (ko) * 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
KR101926419B1 (ko) * 2010-08-30 2018-12-10 스프링 뱅크 파마슈티칼스, 인크. 치료제로서 올리고뉴클레오타이드 유사체의 설계
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
KR101835401B1 (ko) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 키랄 핵산 어쥬번트
SG10201912895PA (en) * 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6502267B2 (ja) * 2013-02-18 2019-04-17 スプリング バンク ファーマシューティカルズ，インコーポレイテッド ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JP6382344B2 (ja) 2014-01-16 2018-08-29 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラルデザイン
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
CN106794188B (zh) * 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
TW201642872A (zh) * 2015-04-07 2016-12-16 春季銀行製藥公司 用於治療ｈｃｖ感染之組成物和方法
US20180185404A1 (en) * 2015-07-02 2018-07-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
US20190070212A1 (en) * 2016-03-11 2019-03-07 Spring Bank Pharmaceuticals, Inc. Compounds and compositions for the treatment of infections
SG11201900154VA (en) * 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
CN111918870B (zh) * 2018-05-18 2022-07-08 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
KR20210015937A (ko) 2018-06-01 2021-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 방광암을 치료하기 위한 방법
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
WO2020036199A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
WO2020114495A1 (zh) * 2018-12-06 2020-06-11 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041C2 (de) 1978-04-19 1987-02-19 Reich Spezialmaschinen GmbH, 7440 Nürtingen Vorrichtung zum Aufteilen von Platten
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
ATE193890T1 (de) 1990-04-18 2000-06-15 Procter & Gamble Pharma Antimikrobielle chinolonyl-lactame
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
KR100691737B1 (ko) 1998-08-10 2007-03-12 이데닉스(케이만)리미티드 Ｂ형 간염의 치료용 β-Ｌ-2'-데옥시-뉴클레오시드
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CZ304886B6 (cs) 2000-07-21 2015-01-07 Gilead Sciences, Inc. Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy
CN100400045C (zh) 2001-05-16 2008-07-09 米珍尼克斯公司 基于核酸的化合物及其使用方法
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
CN102123716B (zh) * 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法

Also Published As

Publication number Publication date
KR101123534B1 (ko) 2012-03-13
EP1968612B1 (en) 2016-03-09
RS54867B1 (sr) 2016-10-31
JP5044854B2 (ja) 2012-10-10
KR101248873B1 (ko) 2013-04-02
US10344046B2 (en) 2019-07-09
US20120264709A1 (en) 2012-10-18
CN101437397B (zh) 2012-09-05
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
US20180273574A1 (en) 2018-09-27
ES2729657T3 (es) 2019-11-05
CN102796155B (zh) 2015-08-26
CN101437397A (zh) 2009-05-20
DK1968612T3 (en) 2017-05-22
SI1968612T1 (sl) 2016-10-28
EP3090748B1 (en) 2019-02-20
SI3090748T1 (sl) 2019-09-30
EP3090748A1 (en) 2016-11-09
CN102796155A (zh) 2012-11-28
WO2007070598A8 (en) 2008-12-31
HRP20160531T1 (hr) 2016-08-12
EP1968612A2 (en) 2008-09-17
US10047114B2 (en) 2018-08-14
IN2015DN01786A (pl) 2015-07-10
US20200087338A1 (en) 2020-03-19
KR20110125677A (ko) 2011-11-21
EP3553072A1 (en) 2019-10-16
US20070149462A1 (en) 2007-06-28
US8691787B2 (en) 2014-04-08
DK3090748T3 (da) 2019-05-27
WO2007070598A9 (en) 2007-11-08
JP2009519345A (ja) 2009-05-14
HUE044034T2 (hu) 2019-09-30
PT3090748T (pt) 2019-06-04
HUE029190T2 (en) 2017-02-28
US8076303B2 (en) 2011-12-13
LT3090748T (lt) 2019-08-26
KR20080072084A (ko) 2008-08-05
CY1121639T1 (el) 2020-07-31
WO2007070598A2 (en) 2007-06-21
CY1117576T1 (el) 2017-04-26
EP1968612A4 (en) 2013-01-09
PL3090748T3 (pl) 2020-03-31
ES2573928T3 (es) 2016-06-13
WO2007070598A3 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
SI1968612T1 (sl) Dinukleotid predzdravila
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006018441D1 (en) Arabinofuranosidasen
DE602006013270D1 (en) Prrs-impfstoffe
DE602006017073D1 (en) Aspartylproteasehemmer
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
DE602006009492D1 (en) Fluidmaschinen
DE602006016951D1 (en) 2-cyanoacrylatzusammensetzung
DE602006009835D1 (en) Nthalten
DE602006014261D1 (en) Benzimidazolverbindungen
DE602006003064D1 (en) Tripeptid- und tetrapeptid-thioether
DE502005007477D1 (en) Delta-sigma-modulator
GB0421294D0 (en) Bioreductively-activated prodrugs
DE502006002219D1 (en) Rotationspumpe
DE602006015303D1 (en) Lecknachweisflicken
DE502006004337D1 (en) Strangführungsrolle
DE502006007734D1 (en) Thiazolcarbonsäureanilide
GB2433078B (en) Structural member
GB0421296D0 (en) Bioreductively-activated prodrugs
GB0515699D0 (en) Prodrugs
HK1122469A (en) Dinucleotide prodrugs
GB0503644D0 (en) Catstep I
GB0421295D0 (en) Bioreductively-activated prodrugs
GB0414567D0 (en) Prodrugs
AU3393P (en) Breakwell xTriticosecale